Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCL Vario System for Corneal Collagen Cross-Linking
NCT04731727Phase 1Not yet recruiting
- Start
- Jun 2021
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 1, open-label, single-arm trial of riboflavin in keratoconus, corneal ectasia, Pellucid marginal degeneration (PMD) and 1 more. Primary endpoints: Best Corrected Visual Acuity at 1 year, Uncorrected Visual Acuity at 1 year and 1 more. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
riboflavin
03
Conditions
keratoconuscorneal ectasiaPellucid marginal degeneration (PMD)keratitis
Beyond the preview
Go deeper on NCT04731727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04731727.